Brought to you by 
GlaxoSmithKline takes 9.9% stake in Korea's Dong-A Pharma
13 May 2010
Executive Summary
Leading South Korean pharmaceutical firm Dong-A Pharmaceutical Co. Ltd. is teaming up with GlaxoSmithKline PLC to co-promote in Korea primary care drugs from each company's portfolio. Concurrently the Big Pharma has acquired a 9.9% stake in Dong-A for £73.9mm ($110.3mm).
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Generic Drugs
- OTC, Consumer
Deal Status
- Final
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
GlaxoSmithKline takes 9.9% stake in Korea's Dong-A Pharma
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice